ONCAlert | 2017 San Antonio Breast Cancer Symposium

Targeting HER2 in Colorectal Cancer

Manish A. Shah, MD
Published Online:11:29 AM, Tue April 11, 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the HERACLES clinical trial, which explored treatment with trastuzumab (Herceptin) and lapatinib (Tykerb) in patients with HER2-amplified metastatic colorectal cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.